ACIU
Q4 2026 EPS Estimate
$-0.22
Nov 3, 2026 · Reports before open
Revenue Estimate
$248,270
FY2027E EPS$0.20
FY2028E EPS$0.37

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
72
Score
8 Buy (89%)1 Hold (11%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
889%
Hold
111%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$7.00
+164.2%
Consensus
$7.00
+164.2%
Bull
$7.00
+164.2%
12-Month Target Range9 analysts
$7.00$7.00$7.00
Current $2.65Consensus
Current Price
$2.65
Upside to Consensus
$4.35

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+344.64%
EPS
FY2028
Rev+20.88%
EPS+83.12%
FY2029
Rev-30.63%
EPS-98.74%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$20M$89M$108M$75M$81M
Low$17M$75M$68M$63M$68M
High$25M$112M$175M$94M$102M
EBITDA Avg$-32M$32M$45M$8M$7M
Low$-53M$25M$19M$7M$7M
High$-31M$39M$117M$8M$7M
EBIT Avg$-34M$28M$39M$761,121$-272,739
Low$-56M$21M$12M$639,472$-419,654
High$-33M$35M$111M$959,876$-182,820
Net Income Avg$-34M$22M$31M$469,619$-439,406
Low$-56M$16M$10M$373,517$-586,321
High$-33M$27M$87M$626,636$-349,487
EPS Avg$-0.42$0.20$0.37$0.00$-0.00
Low$-0.56$0.16$0.10$0.00$-0.01
High$-0.33$0.27$0.87$0.01$-0.00
Analysts (Rev / EPS)2 / 23 / 23 / 31 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$199,559$7M
Low$199,559$7M
High$199,559$7M
EBITDA Avg$-15M$-9M
Low$-15M$-9M
High$-15M$-9M
EBIT Avg$-16M$-10M
Low$-16M$-10M
High$-16M$-10M
Net Income Avg$-16M$-10M
Low$-16M$-10M
High$-16M$-10M
EPS Avg$-0.16$-0.10
Low$-0.16$-0.10
High$-0.16$-0.10
Analysts (Rev / EPS)2 / 12 / 1

Earnings Surprises

Recent Analyst Actions

Mar 13, 2026Jefferies
Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial'
Target:$7.00
+132.9%from $3.00
May 30, 2024BTIG
AC Immune initiated with a Buy at BTIG
Target:$8.00
+101.5%from $3.97
Jul 11, 2022Leerink Partners
SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $10
Target:$10.00
+198.5%from $3.35
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.